Vaccines: a key tool to tackle antimicrobial resistance (AMR)

Vaccines: a key tool to tackle antimicrobial resistance (AMR)

INSIGHT PAPER | May 2024

With drug-resistant bacterial infections causing an estimated 1.27 million deaths per year globally, antimicrobial resistance (AMR) is an urgent global health challenge. This insight paper elucidates the role of immunisation in mitigating AMR, with specific recommendations for governments, the international health community, civil society and academia.

View in web    Download

Human papillomavirus (HPV) vaccine market shaping roadmap

Human papillomavirus (HPV) vaccine market shaping roadmap

INSIGHT PAPER | March 2024

This insight paper provides a non-technical summary of that document. It highlights how working towards a series of key objectives and target outcomes can help achieve a healthy HPV vaccine market, and how doing so can play a major role in turning the ambitious vision of consigning cervical cancer to history into a worldwide reality.

View in web    Download

The Vaccine Investment Strategy (VIS)

The Vaccine Investment Strategy (VIS)

BACKGROUND PAPER | February 2024

The Vaccine Investment Strategy (VIS) enables Gavi to maximise the number of lives it helps save and the number of people whose health it improves, while facilitating long‑term planning for partners, donors, manufacturers and Gavi‑supported countries.

View in web    Download

Learning from COVID-19 to support vaccine delivery during future health emergencies

Learning from COVID-19 to support vaccine delivery during future health emergencies

ANALYSIS PAPER | February 2024

This analysis paper describes the circumstances in which the Gavi Secretariat took on a broader set of roles and responsibilities in supporting COVID-19 vaccine delivery than originally intended and summarises the nature of those contributions.

View in web    Download

Coordination in a crisis: Lessons managing the COVAX Strategic Coordination Office (2021–2023)

Coordination in a crisis: Lessons managing the COVAX Strategic Coordination Office (2021–2023)

WHITE PAPER | December 2023

Drawing upon experiences gained during the COVID-19 pandemic in coordinating the COVAX Strategic Coordination Office (SCO), this paper proposes lessons for future pandemic responses, as well as what might be maintained during intra-pandemic periods, to better prepare for future emergencies.

View in web    Download

2023 MTR report

Raising Generation ImmUnity: The 2023 Mid-Term Review Report

REPORT | June 2023

This report uses data from the first two years of the Alliance’s 2021-2025 strategic period to chart progress against the 2019 Investment Opportunity. The Alliance is on track to meet the majority of the key commitments made to donors. This includes supporting countries to immunise an additional 300 million children by 2025, delivering 3.2 billion vaccines, saving more than seven million lives and generating economic benefits of US$ 80-100 billion.

Download

A preliminary assessment of COVAX’s impact in lower-income countries

A preliminary assessment of COVAX’s impact in lower-income countries

WHITE PAPER | May 2023

Approximately 90% of COVAX-delivered COVID-19 doses have gone to lower-income economies. This represents the fastest and most complex global deployment of vaccines ever. But in terms of achieving equitable access during this pandemic, how successful has it been and where have its impacts been the greatest?

View in web    Download

Malaria vaccine market shaping roadmap

Malaria vaccine market shaping roadmap

WHITE PAPER | April 2023

The development of the world’s first safe and effective malaria vaccine is a truly historic breakthrough. However, to harness its potential to help save many of the more than 600,000 lives claimed by the disease every year, much work still needs to be done. That’s why Gavi, the Vaccine Alliance, is setting out detailed plans to boost supplies of malaria vaccines, lower their costs, improve our understanding of demand, support vaccination programmes and create a supportive environment for future malaria vaccine innovation.

View in web    Download

Building an emergency response decision-making framework for outbreaks of pandemic potential

 

Building an emergency response decision-making framework for outbreaks of pandemic potential

DISCUSSION PAPER | April 2023

When an outbreak of an infectious disease starts to escalate, how should global health organisations decide on if, when and how to launch a response? To this end, Gavi is working with partners to develop a decision-making framework for outbreaks of pandemic potential that will define optimum interventions, specific to the outbreak, and unlock critical financing in response.

View in web    Download

View page

10 Learnings for the Alliance from the COVAX Humanitarian Buffer

DISCUSSION PAPER | February 2023

The following 10 learnings highlight the ways in which the COVAX Humanitarian Buffer (HB) and COVAX’s broader learnings in reaching humanitarian settings can contribute to both the Alliance’s work in routine immunisation, future preparedness and response efforts.

View in web    Download

View page

Gavi Expanding Sustainable Vaccine Manufacturing in Africa 2022

WHITE PAPER | 2 November 2022

The pandemic has highlighted new and pressing challenges to regional vaccine supply resilience as a critical factor in global health security. While 1.8 billion doses1 of COVID-19 vaccine have been shipped under COVAX, including 0.6 billion to Africa, early delays in obtaining doses on the African continent stimulated new resolve to address future supply security.

View in web    Download

View page

COVAX: key learnings for future pandemic preparedness and response

WHITE PAPER | 14 September 2022

Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.

View in web    Download

View page

A New Era of Vaccine Manufacturing in Africa

WHITE PAPER | 22 June 2022

One of the prominent issues exposed by the COVID-19 pandemic is the urgent need to further diversify global vaccine manufacturing, particularly with regards to Africa. With the political realities of nationalism, trade barriers, and the absence of regional manufacturing capability and capacity, rapid and equitable global access to life-saving vaccines can be compromised, leading to delays that put lives at risk.

View in web    Download

View page

Taking stock of humanitarian access to pandemic vaccines

DISCUSSION PAPER | 22 June 2022

COVAX was launched in 2020 with equity as its foundational principle, and fundamental to its design from the outset was a vision to address the most unpredictable and hardest to fill gaps in global COVID-19 vaccine access.

View in web    Download

All Products

COVAX: key learnings for future pandemic preparedness and response

Drawing on COVAX’s unique experience enabling an unprecedented global rollout at scale during a pandemic, this paper outlines the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for the future.

An analysis of sovereign debt and economic risks from COVID-19 in Gavi-supported countries

An analysis of sovereign debt levels in Gavi-supported countries, and the impact of COVID-19 on their economies.

Last updated: 16 May 2024

Subscribe to our newsletter